Trial Profile
A Two-center, Randomized, Double-blind, Placebo-controlled, Phase Ib Study to Assess the Safety, Tolerability and Immunogenicity of Two Ascending Doses of the Candidate Vaccine MVA-MERS-S_DF-1 in Healthy Study Subjects
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 14 Dec 2023
Price :
$35
*
At a glance
- Drugs MVA MERS S (Primary)
- Indications Middle East respiratory syndrome coronavirus
- Focus Adverse reactions; First in man
- 04 Dec 2023 Planned End Date changed from 1 May 2023 to 30 May 2024.
- 06 Nov 2022 Planned primary completion date changed from 1 Oct 2022 to 1 Nov 2022.
- 06 Nov 2022 Status changed from recruiting to active, no longer recruiting.